Trial Profile
A Post-authorization, Observational Study to Assess the Impact of Blue Light Cystoscopy After Administration of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Sep 2014
Price :
$35
*
At a glance
- Drugs Hexyl aminolevulinate (Primary)
- Indications Bladder cancer
- Focus Diagnostic use
- Sponsors GE Healthcare
- 19 Sep 2014 New trial record